International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology

@article{Neubig2003InternationalUO,
  title={International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology},
  author={Richard R. Neubig and Michael Spedding and Terry Kenakin and Arthur Christopoulos},
  journal={Pharmacological Reviews},
  year={2003},
  volume={55},
  pages={597 - 606}
}
The recommendations that follow have been updated from the proposals of a Technical Subcommittee set up by the International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification (Jenkinson DH, Barnard EA, Hoyer D, Humphrey PPA, Leff P, and Shankley NP (1995) International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. IX. Recommendations on terms and symbols in quantitative pharmacology. Pharmacol Rev 47:255–266). 

Tables from this paper

International Union of Basic and Clinical Pharmacology. XC. Multisite Pharmacology: Recommendations for the Nomenclature of Receptor Allosterism and Allosteric Ligands

An overview of allostery as applied to receptor families and approaches for detecting and validating allosteric interactions is presented and recommendations for the nomenclature ofAllosteric ligands and their properties are given.

The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands

The International Union of Basic and Clinical Pharmacology/British Pharmacological Society (IUPHAR/BPS) Guide to PHARMACOLOGY is a new open access resource providing pharmacological, chemical, genetic, functional and pathophysiological data on the targets of approved and experimental drugs.

Drug-Target Association Kinetics in Drug Discovery.

The fall and rise of pharmacology--(re-)defining the discipline?

The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY

This update describes content expansion, new features and interoperability improvements introduced in the 10 releases since August 2015, and introduces the newly funded project for the Guide to IMMUNOPHARMACOLOGY (GtoImmuPdb, www.guidetoimmunopharmacology.org).

Overview of Drug Discovery and Development

This overview unit describes the core activities involved in the drug discovery and development process, from target identification ‐ including preclinical biology, medicinal and process chemistry ‐

Principles of pharmacodynamics and their applications in veterinary pharmacology.

This review introduces and summarizes the principles of PDs and illustrates them with examples drawn from both basic and veterinary pharmacology.

Link between a high k on for drug binding and a fast clinical action: to be or not to be?

The presented simulations tally with a positive link between a drug's effective/observed association rate and the swiftness of its clinical action, and show that the k on-concept should not be confounded with the effective association process.

In vitro models: research in physiology and pharmacology of the lower urinary tract

In this review, representative assays are presented based on the experience in male erectile dysfunction and can be classified by sites of action of drugs into the following categories: receptors, effector enzymes and enzymes that terminate the responses.
...

References

SHOWING 1-10 OF 29 REFERENCES

International Union of Pharmacology. XXXI. Recommendations for the Nomenclature of Multimeric G Protein-Coupled Receptors

A receptor is defined by the International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC-IUPHAR) as a protein, or a complex of proteins, which recognizes

International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels

This issue of Pharmacological Reviews includes a new venture in the collaboration between the International Union of Pharmacology (IUPHAR) and the American Society for Pharmacology and Experimental

pAx and competitive drug antagonism.

  • H. Schild
  • Biology
    British journal of pharmacology and chemotherapy
  • 1949
Guarino and Bovet evolve a new formula for the quantitative relations of antagonistic drugs whereby pA would be dependent on the concentration of active drug in competitive antagonism.

A Pharmacologic Analysis of Drug-Receptor Interaction

Drug receptor/theory seven transmembrane receptor behaviour human recombinant receptor systems stimulus-response mechanisms drug response mechanisms diffusion and drug concentration in receptor

A MODIFICATION OF RECEPTOR THEORY

An attempt has been made to determine the relation between log concentration and effect for acetylcholine and the frog rectus abdominis after blocking the cholinesterase activity of isolated rabbit auricles.

Operational models of pharmacological agonism

  • J. BlackP. Leff
  • Biology
    Proceedings of the Royal Society of London. Series B. Biological Sciences
  • 1983
An alternative model is proposed, representing the cognitive and transducer functions of a receptor, that describes agonist action with one fewer parameter than the traditional model, and provides a chemical definition of intrinsic efficacy making this parameter experimentally accessible in principle.

Analysis of competitive agonist-antagonist interactions by nonlinear regression.

SOME QUANTITATIVE USES OF DRUG ANTAGONISTS

Various applications of pAx measurements are discussed based on the hypothesis that drugs and drug antagonists compete for receptors according to the mass law, and a new measure, pAh, is introduced to express the activity of unsurmountable antagonists.

The ligand paradox between affinity and efficacy: can you be there and not make a difference?

Further analysis of anomalous pKB values for histamine H2‐receptor antagonists on the mouse isolated stomach assay

It is concluded that the apparent varying selectivity of the antagonists for gastric and atrial histamine H2‐receptors may be explained by the differential loss of antagonists into the gastric secretion from the receptor compartment and that there is no need to postulate heterogeneity of histamineH2‐ receptors.